Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.44 |
| ▸ | GSPT1 | P15170 | 3/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.44 |
| ▸ | WIZ | O95785 | 4/20 | 0.44 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.43 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34465616 | 0.95 | CRBN (0.47) | MAPTCRBNGSPT1DDB1IKZF3 | |
| SCHEMBL34466106 | 0.92 | MAPT (0.49) | MAPTCRBNGSPT1DDB1IKZF3 | |
| SCHEMBL34465975 | 0.91 | CRBN (0.51) | CRBNGSPT1DDB1IKZF3WIZ | |
| SCHEMBL34466434 | 0.91 | MAPT (0.46) | MAPTCRBNWIZIKZF2IKZF1 | |
| SCHEMBL34465740 | 0.90 | CRBN (0.49) | CRBNGSPT1DDB1IKZF3WIZ | |
| SCHEMBL34466473 | 0.90 | CRBN (0.50) | CRBNGSPT1DDB1IKZF3IKZF2 | |
| SCHEMBL34465703 | 0.87 | CRBN (0.52) | CRBNGSPT1DDB1IKZF3WIZ | |
| SCHEMBL34466553 | 0.86 | MAPT (0.47) | MAPTCRBNGSPT1DDB1IKZF3 | |
| SCHEMBL34466241 | 0.86 | IKZF2 (0.48) | MAPTCRBNGSPT1DDB1IKZF3 | |
| SCHEMBL34466066 | 0.86 | IKZF2 (0.47) | MAPTCRBNGSPT1DDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | GENOSCO INC (US) | 2026-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | CRBN, PSMB3, PSMB1 | MAPT 3675/4885CRBN 1/4885GSPT1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.